2023 HCPCS Code C9073

Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Notice HCPCS C9073 terminated on March 31, 2021.
Short Description Brexucabtagene autoleucel ca
HCPCS Coverage Code D = Special coverage instructions apply
HCPCS Action Code N = No maintenance for this code
HCPCS Action Effective Date April 01, 2021
HCPCS Code Added Date January 01, 2021
HCPCS Termination Date March 31, 2021
HCPCS Pricing Indicator Code 53 = Statute
HCPCS Multiple Pricing Indicator Code A = Not applicable as HCPCS priced under one methodology
HCPCS Statute Number 1833(T)
HCPCS Cross Reference Code Q2053
HCPCS Type Of Service Code 9 = Other medical items or services
F = Ambulatory surgical center (facility usage for surgical services)
HCPCS Anesthesia Base Unit Quantity 0